Browse medicines, page 14 of 150

Use listed on the medicine record

Acute attacks

Use listed on the medicine record

When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.

Use listed on the medicine record

Directions Turn tube upside down and rotate cap to release pellets into cap. Unscrew cap and without touching pellets tip them into the mouth under the tongue. Allow to dissolve Take 15 minutes before meals.

Use listed on the medicine record

Endometriosis amenable to hormonal management

Use listed on the medicine record

The risk of hospitalization for heart failure

Use listed on the medicine record

Acute iron intoxication

Use listed on the medicine record

Dementia of the Alzheimer's type

Use listed on the medicine record

Doxepin Hydrochloride Capsules, USP are recommended for the treatment of: 1. Psychoneurotic patients with depression and/or anxiety. 2. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). 3. Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). 4. Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders.

Use listed on the medicine record

Hypertension when oral therapy is not practical

Use listed on the medicine record

Suitable for:◆Healthy adults who are concerned aboutrespiratory health;◆Long-term smokers, those exposed tosecond-hand smoke, and people who arelong exposed to dust, harmful gases, andcooking fumes;People with lung problems such as coughsthose with sensitive respiratory systemsthose susceptible to viral infections, andthose with poor immunity

Use listed on the medicine record

Hypertension

Use listed on the medicine record

DIRECTIONS Turn tube upside down and rotate cap to release pellets into cap. Unscrew cap and without touching pellets tip them into the mouth under the tongue. Allow to dissolve Take 15 minutes before meals.

Use listed on the medicine record

Triglyceride (TG) levels

Use listed on the medicine record

Iron deficiency anemia

Use listed on the medicine record

Fidaxomicin tablets are a macrolide antibacterial indicated in adult patients for the treatment of C. difficile -associated diarrhea. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of fidaxomicin tablets and other antibacterial drugs, fidaxomicin tablets should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. ( 1.2 ) 1.1 Clostridioides difficile -Associated Diarrhea Fidaxomicin tablets are indicated in adult patients for the treatment of C. difficile-associated diarrhea (CDAD).

Use listed on the medicine record

Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nauseaand vomiting associated with initial and repeat coursesof highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting.

Use listed on the medicine record

Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.

Use listed on the medicine record

The acute complications of sickle cell disease

Use listed on the medicine record

Adult and pediatric patients aged one month and older

Use listed on the medicine record

Complications due to vaccinia vaccination ( 1 ), including

Use listed on the medicine record

• Aids in the removal of phlegm, mucus, or other secretions associated with occasional sore mouth. • For temporary use in cleansing minor wounds or minor gum inflammation resulting from minor dental procedures, dentures, orthodontic appliances, accidental injury, or other irritations of the mouth and gums. • For temporary use to cleanse canker sores. • Assists in the removal of foreign material from minor oral wounds.

Use listed on the medicine record

REMICADE is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease.

Use listed on the medicine record

INDICATIONS: Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris,…

Use listed on the medicine record

Swollen, red, or tender gums, occasional bad breath, minor toothache, occasional headache, irritability, or fatigue due to sensitivity

Use listed on the medicine record

LUPRON DEPOT 3.75 mg is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Endometriosis Management of endometriosis, including pain relief and reduction of endometriotic lesions. ( 1.1 ) In combination with a norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms. ( 1.1 ) Limitations of Use: The total duration of therapy with LUPRON DEPOT 3.75 mg plus add-back therapy should not exceed 12 months due to concerns about adverse impact on bone mineral density.

Use listed on the medicine record

Heavy menstrual bleeding for up to 5 years

Use listed on the medicine record

KRESLADI is indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplant. This indication is approved under accelerated approval based on increase in neutrophil CD18 and CD11a surface expression [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

Vertigo associated with diseases affecting the vestibular system

Use listed on the medicine record

Pregnancy

Use listed on the medicine record

The risk for weight regain after prior weight loss

Use listed on the medicine record

INDICATIONS Penicillamine tablets are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that penicillamine tablets are not of value in ankylosing spondylitis. Wilson’s Disease Wilson's disease (hepatolenticular degeneration) results from the interaction of an inherited defect and an abnormality in copper metabolism.

Use listed on the medicine record

And pediatric patients ages 3 years and older for the reversal of soft-tissue anesthesia, i

Use listed on the medicine record

This product is designed to help maintain memory, focus, and overall cognitive performance. It supports healthy blood circulation to the brain and enhances communication between brain cells, which are essential for mental clarity and alertness. Regular use may assist in slowing age-related cognitive decline and help protect against early symptoms associated with Alzheimer’s disease and dementia. It provides essential nutrients and antioxidants that help protect brain cells from oxidative stress and support long-term brain health.

Use listed on the medicine record

The treatment of adult patients

Use listed on the medicine record

Moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Use listed on the medicine record

ENDOMETRIN ® is indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. ENDOMETRIN is a progesterone indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks.

Use listed on the medicine record

Postoperative pain

Use listed on the medicine record

Coronavirus disease 2019

Use listed on the medicine record

Relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder

Use listed on the medicine record

Pulmonary arterial hypertension

Use listed on the medicine record

Excess abdominal fat in HIV-infected adult patients with lipodystrophy

Use listed on the medicine record

The signs and symptoms of idiopathic Parkinson's disease

Use listed on the medicine record

Moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers

Use listed on the medicine record

ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD). ENTYVIO is an integrin receptor antagonist indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). ( 1 ) moderately to severely active Crohn's disease (CD). ( 1 )